{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096139","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.721290+00:00","generated_at":"2026-05-31T09:37:58.962633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"aTyr Pharma completes Phase 3 sarcoidosis trial enrollment; Q2 cash $81.4M","bullets":["Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolled 268 patients; topline data expected Q3 2025.","Cash, equivalents, restricted cash and investments totaled $81.4M as of June 30, 2024.","R&D expenses $14.0M, G&A $3.3M for Q2 2024.","Phase 2 EFZO-CONNECT for SSc-ILD enrolling; interim data expected Q2 2025.","Appointed Jayant Aphale VP Technical Operations; research agreement with Stanford for anti-NRP2 in GBM."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096139","json":"https://secwatch.observer/filing/0000950170-24-096139.json","markdown":"https://secwatch.observer/filing/0000950170-24-096139.md","text":"https://secwatch.observer/filing/0000950170-24-096139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024096139/0000950170-24-096139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024096139/atyr-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:37:58.962633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}